Literature DB >> 16723719

Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice.

Erin D MacDougall1, Farah Kramer, Patti Polinsky, Shelley Barnhart, Bardia Askari, Fredrik Johansson, Rebecca Varon, Michael E Rosenfeld, Kazuhiro Oka, Lawrence Chan, Stephen M Schwartz, Karin E Bornfeldt.   

Abstract

Very low-density lipoprotein (VLDL) and LDL plasma levels are associated with cardiovascular mortality. Whereas VLDL/LDL lowering causes regression of early atherosclerotic lesions, less is known about the effects of aggressive lipid lowering on regression of advanced complex lesions. We therefore investigated the effect of VLDL/LDL lowering on pre-existing lesions in LDL receptor-deficient mice. Mice fed a high-fat diet for 16 weeks developed advanced lesions with fibrous caps, necrotic cores, and cholesterol clefts in the brachiocephalic artery. After an additional 14 weeks on a low-fat diet, plasma cholesterol levels decreased from 21.0 +/- 2.6 to 8.4 +/- 0.6 mmol/L, but lesions did not regress. Levels of VLDL/LDL were further lowered by using a helper-dependent adenovirus encoding the VLDL receptor (HD-Ad-VLDLR) under control of a liver-selective promoter. Treatment with HD-Ad-VLDLR together with a low-fat diet regimen resulted in reduced lesion size (cross-sectional area decreased from 146,272 +/- 19,359 to 91,557 +/- 15,738 microm2) and an 89% reduction in the cross-sectional lesion area occupied by macrophages compared to controls. These results show that aggressive VLDL/LDL lowering achieved by hepatic overexpression of VLDLR combined with a low-fat diet regimen induces regression of advanced plaques in the brachiocephalic artery of LDL receptor-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723719      PMCID: PMC1606621          DOI: 10.2353/ajpath.2006.051009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice.

Authors:  Helen Williams; Jason Lee Johnson; Kevin George Stephen Carson; Christopher Langdale Jackson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

2.  Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound.

Authors:  Clemens von Birgelen; Marc Hartmann; Gary S Mintz; Dietrich Baumgart; Axel Schmermund; Raimund Erbel
Journal:  Circulation       Date:  2003-11-17       Impact factor: 29.690

3.  The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression.

Authors:  H C Stary
Journal:  Am J Cardiol       Date:  2001-07-19       Impact factor: 2.778

Review 4.  A risk factor for atherosclerosis: triglyceride-rich lipoproteins.

Authors:  M J Malloy; J P Kane
Journal:  Adv Intern Med       Date:  2001

5.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.

Authors:  Allen J Taylor; Steven M Kent; Patrick J Flaherty; Louis C Coyle; Thor T Markwood; Marina N Vernalis
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

6.  Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model.

Authors:  E D Reis; J Li; Z A Fayad; J X Rong; D Hansoty; J G Aguinaldo; J T Fallon; E A Fisher
Journal:  J Vasc Surg       Date:  2001-09       Impact factor: 4.268

Review 7.  Rupture of the atherosclerotic plaque: does a good animal model exist?

Authors:  Paul Cullen; Roberta Baetta; Stefano Bellosta; Franco Bernini; Giulia Chinetti; Andrea Cignarella; Arnold von Eckardstein; Andrew Exley; Martin Goddard; Marten Hofker; Eva Hurt-Camejo; Edwin Kanters; Petri Kovanen; Stefan Lorkowski; William McPheat; Markku Pentikäinen; Jürgen Rauterberg; Andrew Ritchie; Bart Staels; Benedikt Weitkamp; Menno de Winther
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-06       Impact factor: 8.311

Review 8.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-14       Impact factor: 29.690

9.  Intraplaque hemorrhage and progression of coronary atheroma.

Authors:  Frank D Kolodgie; Herman K Gold; Allen P Burke; David R Fowler; Howard S Kruth; Deena K Weber; Andrew Farb; L J Guerrero; Motoya Hayase; Robert Kutys; Jagat Narula; Aloke V Finn; Renu Virmani
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

10.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

View more
  19 in total

1.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

2.  Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor.

Authors:  Debapriya Basu; Yunying Hu; Lesley-Ann Huggins; Adam E Mullick; Mark J Graham; Tomasz Wietecha; Shelley Barnhart; Allison Mogul; Katharina Pfeiffer; Andreas Zirlik; Edward A Fisher; Karin E Bornfeldt; Florian Willecke; Ira J Goldberg
Journal:  Circ Res       Date:  2018-01-10       Impact factor: 17.367

3.  Interleukin-7 induces recruitment of monocytes/macrophages to endothelium.

Authors:  Rongying Li; Antoni Paul; Kerry W S Ko; Michael Sheldon; Benjamin E Rich; Tomoya Terashima; Carrie Dieker; Shelley Cormier; Lan Li; Elie A Nour; Lawrence Chan; Kazuhiro Oka
Journal:  Eur Heart J       Date:  2011-07-30       Impact factor: 29.983

Review 4.  Macrophage Phenotype and Function in Different Stages of Atherosclerosis.

Authors:  Ira Tabas; Karin E Bornfeldt
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

5.  Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Anne-Laure Sberna; Mahfoud Assem; Rui Xiao; Steve Ayers; Thomas Gautier; Boris Guiu; Valérie Deckert; Angélique Chevriaux; Jacques Grober; Naig Le Guern; Jean-Paul Pais de Barros; David D Moore; Laurent Lagrost; David Masson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-21       Impact factor: 8.311

Review 6.  Progression and disruption of advanced atherosclerotic plaques in murine models.

Authors:  Michael E Rosenfeld; Michelle M Averill; Brian J Bennett; Stephen M Schwartz
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

7.  Up-regulation of VLDL receptor expression and its signaling pathway induced by VLDL and beta-VLDL.

Authors:  Zhiguo Liu; He Li; Yinghong Li; Yan Wang; Yiqiang Zong; Youmei Feng; Zongchen Feng; Yaozu Deng; Shen Qu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

8.  A Novel Strategy to Prevent Advanced Atherosclerosis and Lower Blood Glucose in a Mouse Model of Metabolic Syndrome.

Authors:  Jenny E Kanter; Farah Kramer; Shelley Barnhart; Jeffrey M Duggan; Masami Shimizu-Albergine; Vishal Kothari; Alan Chait; Stephan D Bouman; Jessica A Hamerman; Bo F Hansen; Grith S Olsen; Karin E Bornfeldt
Journal:  Diabetes       Date:  2018-02-26       Impact factor: 9.461

9.  Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis.

Authors:  P-J Guns; T Van Assche; W Verreth; P Fransen; B Mackness; M Mackness; P Holvoet; H Bult
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

10.  Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice.

Authors:  Fredrik Johansson; Farah Kramer; Shelley Barnhart; Jenny E Kanter; Tomas Vaisar; Rachel D Merrill; Linda Geng; Kazuhiro Oka; Lawrence Chan; Alan Chait; Jay W Heinecke; Karin E Bornfeldt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.